STRUCTURAL GENOMICS CONSORTIUM

• ◆

  7 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

CT Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“These financial statements have been prepared on the basis of accounting principles applicable to a "going concern", which assume that SGC will continue in operation for the foreseeable future, for a period of at least 12 months from the date of signing these financial statements and will be able to realise its assets and discharge its liabilities in the normal course of operations. Phase V, which ended on 30 June 2025, has sufficient existing and future committed funds to cover expected obligations to 31 December 2025. The application for Phase VI funding from the IHI program has been approved, and the application has advanced to the contracting phase, which is expected to be completed by November 2025, therefore the Directors are satisfied the financial statements can be prepared on a going concern basis.”

Significant events

• “Phase V of SGC ended on 30 June 2025, we received a 6-month no cost extension for the EUbOPEN grant. SGC is commencing operations for Phase VI, which will begin on 01 December 2025”
• “The grant proposal for the Horizon program has been reviewed positively and is entering the contracting phase. As a result, the next major infusion of funding is expected in November 2025, but no later than December 2025.”
• “SGC and its partnered universities won an award of €31,000,000 from the European Commission as part of the IMI for a project called EUbOPEN covering the five-year period ending 30 June 2025. In March 2025, the IMI granted the project a no-cost extension until 31 October 2025.”
• “SGC received €1,100,000 in August 2025 as its final instalment from Bristol-Myers Squibb's initial funding commitment of €5,500,000.”
• “The BMGF has provided an additional grant to SGC which began on 1 September 2024 and will end on 31 August 2027, to support early drug discovery research in the amount of US$ 4,353,147.”
• “The SGC has received a sub-award from the University of Dundee from the Michael J. Fox Foundation in the amount of US$ 1,605,070.”
• “In August 2021, the Michael J. Fox Foundation awarded SGC US$ 500,000 for a new research initiative focusing on the WD domain of LRRK2.”
• “During the year, SGC received USD 250,000 from Schrodinger, Inc to be used in research for Huntington's Disease.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

0

last 24 months

Officers appointed

5

last 12 months

Officers resigned

7

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +67,214.3%

  -£7,000 → £4,698,000

• Cash

  -32.8%

  £2,570,000 → £1,728,000

• Net assets

  -10.7%

  £3,880,000 → £3,465,000

• Employees

  —

  Not reported

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers